查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1888714

美国骨关节炎治疗市场规模、份额和趋势分析报告：按产品、应用、主要用户和细分市场预测（2025-2033 年）

U.S. Osteoarthritis Therapeutics Market Size, Share & Trends Analysis Report By Product (Viscosupplements, Platelet-Rich Plasma Therapy, Adipose Tissue Therapy, Bone Graft Substitutes), By Application, By Primary User, And Segment Forecasts, 2025 - 2033
出版日期: | 出版商: Grand View Research | 英文 190 Pages | 商品交期: 2-10个工作天内

价格

美国骨关节炎治疗市场摘要

据估计，2024年美国骨关节炎治疗市场规模为21.5亿美元，预计2033年将达45亿美元。

预计 2025 年至 2033 年的复合年增长率将达到 8.61%。人口老化加剧、肥胖和关节损伤的盛行率上升，以及对微创治疗和再生医学的需求不断增长，正在推动骨关节炎治疗产业的发展。

人口老化是市场成长的主要驱动力。根据美国疾病管制与预防中心（CDC）的数据，截至2024年2月，美国18岁及以上美国的年龄调整后关节炎盛行率为18.9%，而75岁及以上成年人的盛行率则高达53.9%。随着美国美国老化，针对老年人的骨关节炎治疗需求日益增长，尤其是在预计2030年老年人口将占总人口约20%的情况下。 2024年9月，CDC报告称，2021年8月至2023年8月期间，40.3%的美国成年人被归类为肥胖。肥胖是骨关节炎的重要危险因素，尤其是在负重关节，其高盛行率导致骨关节炎病例数量不断增加。

此外，与运动和工伤事故相关的关节损伤日益增多，也加速了骨关节炎的发展。随着越来越多人参与体育活动，他们的关节损伤以及随后发展为骨关节炎的风险也随之增加。 2024年2月，国际劳工组织（ILO）估计，全球每年约有3.95亿工人遭受非致命性工伤，其中许多会导致关节损伤。这提高了人们对关节健康管理必要性的认识，也促使美国对骨关节炎治疗的需求不断增长。

最后，微创和再生医学的兴起正在对美国骨关节炎治疗市场产生关键影响。人们对非手术治疗方法，例如透明质酸注射、富血小板血浆（PRP）疗法和干细胞疗法，越来越感兴趣，因为与传统手术治疗相比，这些疗法具有恢復期短、副作用少等优势，是更有效的替代方案。预计这种治疗方法偏好的转变将在未来几年继续推动市场成长。

人口老化、肥胖率上升、关节损伤增加以及人们对微创和再生医学日益增长的需求，是推动该产业发展的主要因素。预计这些因素将支撑市场的持续成长，而治疗技术的进步将在满足老龄化社会的需求方面发挥关键作用。

目录

第一章调查方法和范围

第二章执行摘要

第三章美国骨关节炎治疗市场变数、趋势与范围

  • 市场谱系展望
  • 市场动态
  • 商业环境分析
    • 产业分析—波特五力分析
    • PESTLE分析
    • 管道分析
    • 专利到期分析
    • 定价分析

第四章美国骨关节炎治疗市场：按产品分類的业务分析

  • 按产品分類的市场份额（2024 年和 2033 年）
  • 按产品分類的市场规模、预测和趋势分析（2021-2033 年）
  • 黏弹性补充剂
  • 富血小板血浆（PRP）疗法
  • 骨移植替代物
  • 骨髓抽吸浓缩液（BMAC）疗法
  • 脂肪组织疗法
  • 自体软骨细胞移植术（ACI），包括MACI
  • 干细胞（其他）
  • 其他的

第五章美国骨关节炎治疗市场：按应用领域分類的业务分析

  • 按应用领域分類的市场份额（2024 年和 2033 年）
  • 按应用领域分類的市场规模、预测和趋势分析（2021-2033 年）
  • 膝骨关节炎
  • 髋关节骨关节炎
  • 肩关节骨关节炎
  • 脊椎骨关节炎
  • 踝关节和足部骨关节炎
  • 其他的

第六章美国骨关节炎治疗市场：主要用户业务分析

  • 主要用户市场占有率（2024 年和 2033 年）
  • 主要用户市场规模、预测与趋势分析（2021-2033）
  • 骨科医生
  • 风湿症医师
  • 运动医学专家
  • 再生医学专家
  • 其他的

第七章 竞争情势

  • 参与企业概况
  • 企业市场分析
  • 公司分类
  • 策略规划
  • 公司简介/列表
    • Stryker
    • Zimmer Biomet Holdings, Inc.
    • Medtronic
    • Anika Therapeutics, Inc.
    • Bioventus
    • Vericel Corporation
    • Smith &Nephew
    • Fidia Farmaceutici SpA
    • Seikagaku Corporation
    • Sanofi
Product Code: GVR-4-68040-817-6

U.S. Osteoarthritis Therapeutics Market Summary

The U.S. osteoarthritis therapeutics market size was estimated at USD 2.15 billion in 2024 and is projected to reach USD 4.50 billion by 2033, growing at a CAGR of 8.61% from 2025 to 2033. Growing geriatric population, rising prevalence of obesity and joint injuries, and increasing demand for minimally invasive and regenerative therapies are driving the osteoarthritis therapeutics industry.

The aging population is a major factor driving the growth of the market. According to the Centers for Disease Control and Prevention (CDC), in February 2024, the age-adjusted prevalence of arthritis among U.S. adults aged 18 and older was 18.9%, with the prevalence in adults aged 75 and older reaching 53.9%. As the U.S. population ages, particularly with the elderly demographic projected to represent nearly 20% of the population by 2030, the demand for osteoarthritis treatments tailored to the older age group is increasing. In September 2024, the CDC reported that 40.3% of U.S. adults were classified as obese between August 2021 and August 2023. Obesity is a significant risk factor for osteoarthritis, especially in weight-bearing joints, and its high prevalence is contributing to the rising number of osteoarthritis cases.

Additionally, the increase in joint injuries, particularly those related to sports and work-related accidents, is accelerating the onset of osteoarthritis. As more individuals engage in physical activities, the likelihood of joint damage and subsequent osteoarthritis increases. In February 2024, the International Labour Organization (ILO) estimated that approximately 395 million workers worldwide sustain non-fatal work injuries annually, many of which result in joint damage. This has increased awareness of the need for joint health management and has contributed to the rising demand for osteoarthritis therapeutics in the U.S.

Finally, the shift toward minimally invasive and regenerative therapies is playing a significant role in shaping the U.S. osteoarthritis therapeutics market. There is growing interest in non-surgical treatments, such as hyaluronic acid injections, platelet-rich plasma (PRP) therapy, and stem cell therapies, as they offer effective alternatives with shorter recovery times and fewer side effects compared to traditional surgical options. This shift in treatment preferences is expected to continue fueling market growth in the coming years.

The industry is driven by the aging population, rising obesity rates, increasing joint injuries, and a growing preference for minimally invasive and regenerative therapies. These factors are expected to support continued market growth, with advancements in treatment technologies playing a key role in meeting the demands of an aging population.

U.S. Osteoarthritis Therapeutics Market Report Segmentation

This report forecasts revenue growth at the country level and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the U.S. osteoarthritis therapeutics market report based on product, application, and primary user:

  • Product Outlook (Revenue, USD Million, 2021 - 2033)
  • Viscosupplements
  • Platelet-Rich Plasma (PRP) Therapy
  • Bone Graft Substitutes
  • BMAC (Bone Marrow Aspirate Concentrate) Therapy
  • Adipose Tissue Therapy
  • Autologous Chondrocyte Implantation (ACI), Including MACI
  • Stem Cell (other)
  • Other (Cartilage Resurfacing Products)
  • Application Outlook (Revenue, USD Million, 2021 - 2033)
  • Knee Osteoarthritis
  • Hip Osteoarthritis
  • Shoulder Osteoarthritis
  • Spine Osteoarthritis
  • Ankle & Foot Osteoarthritis
  • Other
  • Primary User Outlook (Revenue, USD Million, 2021 - 2033)
  • Orthopedic Surgeons
  • Rheumatologists
  • Sports Medicine Specialists
  • Regenerative Medicine Specialists
  • Other

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Product
    • 1.2.2. Application
    • 1.2.3. Primary User
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. U.S. Osteoarthritis Therapeutics Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis
    • 3.3.3. Pipeline Analysis
    • 3.3.4. Patent Expiry Analysis
    • 3.3.5. Pricing Analysis

Chapter 4. U.S. Osteoarthritis Therapeutics Market: Product Business Analysis

  • 4.1. Product Market Share, 2024 & 2033
  • 4.2. Product Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Product, 2021 to 2033 (USD Million)
  • 4.4. Viscosupplements
    • 4.4.1. Viscosupplements Market, 2021 - 2033 (USD Million)
  • 4.5. Platelet-Rich Plasma (PRP) Therapy
    • 4.5.1. Platelet-Rich Plasma (PRP) Therapy Market, 2021 - 2033 (USD Million)
  • 4.6. Bone Graft Substitutes
    • 4.6.1. Bone Graft Substitutes Market, 2021 - 2033 (USD Million)
  • 4.7. BMAC (Bone Marrow Aspirate Concentrate) Therapy
    • 4.7.1. BMAC (Bone Marrow Aspirate Concentrate) Therapy Market, 2021 - 2033 (USD Million)
  • 4.8. Adipose Tissue Therapy
    • 4.8.1. Adipose Tissue Therapy Market, 2021 - 2033 (USD Million)
  • 4.9. Autologous Chondrocyte Implantation (ACI), Including MACI
    • 4.9.1. Autologous Chondrocyte Implantation (ACI), Including MACI Market, 2021 - 2033 (USD Million)
  • 4.10. Stem Cell (other)
    • 4.10.1. Stem Cell (other) Market, 2021 - 2033 (USD Million)
  • 4.11. Others
    • 4.11.1. Others Market, 2021 - 2033 (USD Million)

Chapter 5. U.S. Osteoarthritis Therapeutics Market: Application Business Analysis

  • 5.1. Application Market Share, 2024 & 2033
  • 5.2. Application Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by application, 2021 to 2033 (USD Million)
  • 5.4. Knee Osteoarthritis
    • 5.4.1. Knee Osteoarthritis Market, 2021 - 2033 (USD Million)
  • 5.5. Hip Osteoarthritis
    • 5.5.1. Hip Osteoarthritis Market, 2021 - 2033 (USD Million)
  • 5.6. Shoulder Osteoarthritis
    • 5.6.1. Shoulder Osteoarthritis Market, 2021 - 2033 (USD Million)
  • 5.7. Spine Osteoarthritis
    • 5.7.1. Spine Osteoarthritis Market, 2021 - 2033 (USD Million)
  • 5.8. Ankle & Foot Osteoarthritis
    • 5.8.1. Ankle & Foot Osteoarthritis Market, 2021 - 2033 (USD Million)
  • 5.9. Others
    • 5.9.1. Others Market, 2021 - 2033 (USD Million)

Chapter 6. U.S. Osteoarthritis Therapeutics Market: Primary User Business Analysis

  • 6.1. Primary User Market Share, 2024 & 2033
  • 6.2. Primary User Segment Dashboard
  • 6.3. Market Size & Forecasts and Trend Analysis, by primary user, 2021 to 2033 (USD Million)
  • 6.4. Orthopedic Surgeons
    • 6.4.1. Orthopedic Surgeons Market, 2021 - 2033 (USD Million)
  • 6.5. Rheumatologists
    • 6.5.1. Rheumatologists Market, 2021 - 2033 (USD Million)
  • 6.6. Sports Medicine Specialists
    • 6.6.1. Sports Medicine Specialists Market, 2021 - 2033 (USD Million)
  • 6.7. Regenerative Medicine Specialists
    • 6.7.1. Regenerative Medicine Specialists Market, 2021 - 2033 (USD Million)
  • 6.8. Others
    • 6.8.1. Others Market, 2021 - 2033 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Participant Overview
  • 7.2. Company Market Position Analysis
  • 7.3. Company Categorization
  • 7.4. Strategy Mapping
  • 7.5. Company Profiles/Listing
    • 7.5.1. Stryker
      • 7.5.1.1. Overview
      • 7.5.1.2. Financial Performance
      • 7.5.1.3. Product Benchmarking
      • 7.5.1.4. Strategic Initiatives
    • 7.5.2. Zimmer Biomet Holdings, Inc.
      • 7.5.2.1. Overview
      • 7.5.2.2. Financial Performance
      • 7.5.2.3. Product Benchmarking
      • 7.5.2.4. Strategic Initiatives
    • 7.5.3. Medtronic
      • 7.5.3.1. Overview
      • 7.5.3.2. Financial Performance
      • 7.5.3.3. Product Benchmarking
      • 7.5.3.4. Strategic Initiatives
    • 7.5.4. Anika Therapeutics, Inc.
      • 7.5.4.1. Overview
      • 7.5.4.2. Financial Performance
      • 7.5.4.3. Product Benchmarking
      • 7.5.4.4. Strategic Initiatives
    • 7.5.5. Bioventus
      • 7.5.5.1. Overview
      • 7.5.5.2. Financial Performance
      • 7.5.5.3. Product Benchmarking
      • 7.5.5.4. Strategic Initiatives
    • 7.5.6. Vericel Corporation
      • 7.5.6.1. Overview
      • 7.5.6.2. Financial Performance
      • 7.5.6.3. Product Benchmarking
      • 7.5.6.4. Strategic Initiatives
    • 7.5.7. Smith & Nephew
      • 7.5.7.1. Overview
      • 7.5.7.2. Financial Performance
      • 7.5.7.3. Product Benchmarking
      • 7.5.7.4. Strategic Initiatives
    • 7.5.8. Fidia Farmaceutici S.p.A.
      • 7.5.8.1. Overview
      • 7.5.8.2. Financial Performance
      • 7.5.8.3. Product Benchmarking
      • 7.5.8.4. Strategic Initiatives
    • 7.5.9. Seikagaku Corporation
      • 7.5.9.1. Overview
      • 7.5.9.2. Financial Performance
      • 7.5.9.3. Product Benchmarking
      • 7.5.9.4. Strategic Initiatives
    • 7.5.10. Sanofi
      • 7.5.10.1. Overview
      • 7.5.10.2. Financial Performance
      • 7.5.10.3. Product Benchmarking
      • 7.5.10.4. Strategic Initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 US osteoarthritis therapeutics market, by product, 2021 - 2033 (USD Million)
  • Table 4 US osteoarthritis therapeutics market, by application, 2021 - 2033 (USD Million)
  • Table 5 US osteoarthritis therapeutics market, by primary user, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 U.S. Osteoarthritis therapeutics market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Therapeutic approach outlook (USD Million)
  • Fig. 10 Competitive landscape
  • Fig. 11 U.S. Osteoarthritis therapeutics market dynamics
  • Fig. 12 U.S. Osteoarthritis therapeutics market: Porter's five forces analysis
  • Fig. 13 U.S. Osteoarthritis therapeutics market: PESTLE analysis
  • Fig. 14 Product market, 2021 - 2033 (USD Million)
  • Fig. 15 Viscosupplements market, 2021 - 2033 (USD Million)
  • Fig. 16 Platelet-Rich Plasma (PRP) Therapy market, 2021 - 2033 (USD Million)
  • Fig. 17 Bone Graft Substitutes market, 2021 - 2033 (USD Million)
  • Fig. 18 BMAC (Bone Marrow Aspirate Concentrate) Therapy market, 2021 - 2033 (USD Million)
  • Fig. 19 Adipose Tissue Therapy market, 2021 - 2033 (USD Million)
  • Fig. 20 Autologous Chondrocyte Implantation (ACI), Including MACI market, 2021 - 2033 (USD Million)
  • Fig. 21 Stem Cell (other) Substitutes market, 2021 - 2033 (USD Million)
  • Fig. 22 Others market, 2021 - 2033 (USD Million)
  • Fig. 23 Application market, 2021 - 2033 (USD Million)
  • Fig. 24 Knee Osteoarthritis market, 2021 - 2033 (USD Million)
  • Fig. 25 Hip Osteoarthritis market, 2021 - 2033 (USD Million)
  • Fig. 26 Shoulder Osteoarthritis market, 2021 - 2033 (USD Million)
  • Fig. 27 Spine Osteoarthritis market, 2021 - 2033 (USD Million)
  • Fig. 28 Ankle & Foot Osteoarthritis market, 2021 - 2033 (USD Million)
  • Fig. 29 Others market, 2021 - 2033 (USD Million)
  • Fig. 30 Primary User market, 2021 - 2033 (USD Million)
  • Fig. 31 Orthopedic Surgeons market, 2021 - 2033 (USD Million)
  • Fig. 32 Rheumatologists market, 2021 - 2033 (USD Million)
  • Fig. 33 Sports Medicine Specialists market, 2021 - 2033 (USD Million)
  • Fig. 34 Regenerative Medicine Specialists market, 2021 - 2033 (USD Million)
  • Fig. 35 Others market, 2021 - 2033 (USD Million)